Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies
- PMID: 8294059
Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies
Abstract
From March, 1990 to February, 1992, we administered fluconazole as antifungal prophylaxis at doses of 3-5 mg/kg/day to 40 patients with prolonged and severe neutropenia following intensive chemotherapy. Fungemia was observed in 3 out 40 patients, and all three of them were due to Candida non-albicans strains: two Candida parapsilosis and one Candida guilliermondi. In vitro sensitivity tests showed that all three isolated strains were susceptible to amphotericin. In one case, Candida guilliermondi was tested for sensitivity to fluconazole and found to be resistant. We conclude that fluconazole prophylaxis proved effective in preventing Candida albicans infections, but it could also contribute to the emergence of Candida non-albicans strains. It might be possible that fluconazole at higher doses could prevent the selection of less susceptible Candida strains.
Similar articles
-
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.Bone Marrow Transplant. 2001 Nov;28(9):873-8. doi: 10.1038/sj.bmt.1703252. Bone Marrow Transplant. 2001. PMID: 11781648
-
Fluconazole resistance of Candida krusei.Boll Ist Sieroter Milan. 1991-1992;70(1-2):527-9. Boll Ist Sieroter Milan. 1991. PMID: 1670057
-
Microbial profile and drug resistance of Candida strains isolated from the blood of children: an 11-year study.Mycoses. 2009 Mar;52(2):149-53. doi: 10.1111/j.1439-0507.2008.01560.x. Epub 2008 Jun 21. Mycoses. 2009. PMID: 18627468
-
[Changes in epidemiology of opportunistic infections due to Candida].Rev Clin Esp. 1995 Oct;195 Suppl 3:1-3. Rev Clin Esp. 1995. PMID: 9441300 Review. Spanish. No abstract available.
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
Cited by
-
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.Drugs. 1995 Oct;50(4):658-90. doi: 10.2165/00003495-199550040-00007. Drugs. 1995. PMID: 8536553 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical